[{"id":"41656404-5e54-4216-8a7c-b90090a6806a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06791460","created_at":"2025-02-25T18:53:09.303Z","updated_at":"2025-02-25T18:53:09.303Z","phase":"Phase 2/3","brief_title":"Pegylated Liposomal Doxorubicin Plus Adebrelimab with or Without Mirabegron in Relapsed Ovarian Cancer","source_id_and_acronym":"NCT06791460","lead_sponsor":"Obstetrics \u0026 Gynecology Hospital of Fudan University","biomarkers":" CD8","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • AiRuiLi (adebrelimab) • mirabegron"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 296","initiation":"Initiation: 02/15/2025","start_date":" 02/15/2025","primary_txt":" Primary completion: 02/14/2028","primary_completion_date":" 02/14/2028","study_txt":" Completion: 02/14/2030","study_completion_date":" 02/14/2030","last_update_posted":"2025-01-24"},{"id":"df92884d-8250-4a24-9227-c6e0152c5621","acronym":"","url":"https://clinicaltrials.gov/study/NCT06534762","created_at":"2025-02-26T12:22:35.503Z","updated_at":"2025-02-26T12:22:35.503Z","phase":"Phase 2","brief_title":"Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study","source_id_and_acronym":"NCT06534762","lead_sponsor":"Zhejiang Provincial People's Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mirabegron"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 07/15/2024","start_date":" 07/15/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-08-02"},{"id":"fca6fe2f-706b-4bc8-9d90-aea678116342","acronym":"SAKK 33/14","url":"https://clinicaltrials.gov/study/NCT02311569","created_at":"2021-01-18T10:56:39.363Z","updated_at":"2024-07-02T16:36:59.538Z","phase":"Phase 2","brief_title":"Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation","source_id_and_acronym":"NCT02311569 - SAKK 33/14","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mirabegron"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2019-05-15"}]